TITLE

IRIS/FUJIREBIO CO-DEVELOP 3GEMS HEMATOLOGY ANALYZER LINE

PUB. DATE
May 2011
SOURCE
Worldwide Biotech;May2011, Vol. 23 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the joint development agreement entered by IRIS International, Inc. and Fujirebio Inc. to develop the IRIS 3GEMS(TM) Hematology Analyzer product line. A total of 6 million U.S. dollars will be contributed by Fujirebio to the program, which will be used to speed up the development of the product. Tokyo, Japan-based Fujirebio is the leading Japanese in vitro diagnostics (IVD) company that offers IVD development, manufacturing and commercialization while IRIS International focuses on products for living cell form analysis.
ACCESSION #
60242736

 

Related Articles

  • IRIS, Fujirebio ink Japanese development accord.  // Biomedical Business & Technology;May2011, Vol. 34 Issue 5, p12 

    The article reports on an agreement signed by Chatsworth, California-based IRIS International with Fujirebio of Tokyo for the joint development of the IRIS 3GEMS hematology analyzer product line.

  • Biotechnology --- A Challenge for the Modern Contract Manufacturer. Lambert, Rolf // Pharmaceutical Technology Europe;Mar2003 Supplement, Vol. 15, p31 

    Discusses ways to achieve the synergistic cooperation between European contract manufacturing organizations (CMO) and biotechnology firms. Reasons for outsourcing; Services offered by a CMO; Attributes of a good CMO; Gap between the cultures and business methods of biotechnology firms and...

  • IRIS, Fujirebio ink Japanese development accord.  // Medical Device Daily;4/7/2011, Vol. 15 Issue 67, p6 

    The article reports that Iris International based in California has entered into a joint development agreement with Fujirebio of Tokyo, Japan for the co-development of the IRIS 3GEMS hematology analyzer product line.

  • New Report Finds Biotechnology Companies are Participating in 39% of All Projects in Development for New Medicines and Technologies for Neglected Diseases.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article focuses on a report from Biotechnology Industry Organization (BIO) and BIO Ventures for Global Health (BVGH) which informs about the innovation brought about by the small to medium sized biotechnology companies in the healthcare. It reports that product development partnerships are...

  • The Timing of Codevelopment Alliances in New Product Development Processes: Returns for Upstream and Downstream Partners. Fang, Eric (Er); Jongkuk Lee; Zhi Yang // Journal of Marketing;Jan2015, Vol. 79 Issue 1, p64 

    Upstream biotech firms (i.e., upstream partners) and downstream pharmaceutical firms (i.e., downstream partners) often form alliances to cope with performance uncertainty and to exploit product specificity in new product development. Although the performance implications of such alliances have...

  • DAVID PARTNERING WITH GOLIATH: IMPACT OF ALLIANCE DEPTH AND PRODUCT DEVELOPMENT ORIENTATION ON ENTREPRENEURIAL SUCCESS. HORA, MANPREET; DUTTA, DEV K. // Academy of Management Annual Meeting Proceedings;2010, Vol. 2010 Issue 1, p1 

    We examine the association between alliances formation (biotech firms and pharmaceutical players) and entrepreneurial success. Employing regression analysis on 1408 biotech firms, we find that alliance depth depicts an inverted U-shape relationship with the likelihood of success. Moreover,...

  • Biotechnology Company Deals With Other Biotechnology Companies: July 1-August 20, 2009.  // BioWorld Insight;8/24/2009, Vol. 17 Issue 34, p7 

    The article offers information on the agreements made between biotechnology companies in July and August 2009. Acorda Therapeutics Inc. made a licensing agreement with Biogen Idec Inc. for the Fampridine-SR, while Ambrilia Biopharma Inc. may receive 15 million dollars from Kotinos...

  • Protecting knowledge in strategic alliances: Resource and relational characteristics. Norman, Patricia M. // Journal of High Technology Management Research;Autumn2002, Vol. 13 Issue 2, p177 

    Presents a study which examined factors associated with the knowledge protection of firms from unwanted appropriation by an alliance partner. Analysis of how resource-based and relational characteristics of high-technology alliances affect the actions of a partner to protect its own...

  • Lessons Learned.  // Pharmaceutical Processing;Jul2012, Vol. 27 Issue 6, p14 

    The article focuses on the survey conducted by Nice Insight which aims to track the outsourcing behaviors in the drug development and biotechnology industry in the U.S. It notes that the survey comprises several questions which were presented to each respondent to gather baseline information on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics